BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Oxycodone (Xtampza ER) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Oxycodone (Xtampza ER)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05761860-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Oxycodone (Xtampza ER): Phase 1 readout est. (NCT05761860)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 1.\nStudy: The Potential of Oxyt
 ocin to Reduce Opioid Abuse Liability and Pain Among Older Adults\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/oxycodone-xtampza-er#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05761860
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05265052-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Oxycodone (Xtampza ER): Phase 2 readout est. (NCT05265052)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 2.\nStudy: 3D1002 in Combination
  With Oxycodone Hydrochloride Sustained-release Tablets in Patients With M
 oderate to Severe Cancer Pain\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/oxycodone-xtampza-e
 r#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 265052
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03054831-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT03054831)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: The Effect of General
  Anesthesia on Pharmacokinetics of Oxycodone in Pediatric\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/oxycodone-xtampza-er#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03054831
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500793-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Oxycodone (Xtampza ER): Phase 1 readout est. (NCT06500793)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 1.\nStudy: Single Dose Study\, P
 harmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF
 614-MPAR-102)\nEstimated primary completion: 22 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06500793
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04218409-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Oxycodone (Xtampza ER): Phase 1 readout est. (NCT04218409)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 1.\nStudy: Opioid-Sparing and Pa
 in-Reducing Properties of Syntocinon: A Dose-Effect Determination\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04218409
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06721988-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Oxycodone (Xtampza ER): Phase na readout est. (NCT06721988)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase na\, Chronic Pain.\nStudy: Effec
 t of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chron
 ification of Acute Post-operative Pain\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/oxycodo
 ne-xtampza-er#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06721988
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05548582-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Oxycodone (Xtampza ER): Phase na readout est. (NCT05548582)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase na.\nStudy: Reduced Opioid Presc
 ription After Laparoscopic Hysterectomy\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/oxycod
 one-xtampza-er#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05548582
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813026-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT07813026)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: Abuse Potential of Ga
 bapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Health
 y\, Non-Drug-Dependent\, Recreational Opioid Users\nEstimated primary comp
 letion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/oxycodone-xtampza-er#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07813026
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06338865-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Oxycodone (Xtampza ER): Phase na readout est. (NCT06338865)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase na.\nStudy: Short Title: Standar
 d vs. Lower Pressure Pneumoperitoneum\nEstimated primary completion: April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/oxycodone-xtam
 pza-er#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06338865
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02044497-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT02044497)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: Population Pharmacoki
 netics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patien
 ts\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT02044497
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821931-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT07821931)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: Suzetrigine in Tonsil
 lectomy for Opioid-sparing Pain Management\nEstimated primary completion: 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/oxycodone-
 xtampza-er#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07821931
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03105518-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT03105518)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: Predictors of Postope
 rative Pain Following Oocyte Retrieval for Assisted Reproduction\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/oxycodone-xtampza-er#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03105518
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07435077-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT07435077)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: Examining Analgesic S
 ynergy and Efficacy in Trauma Care\nEstimated primary completion: July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/oxycodone-xtampza-
 er#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7435077
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750639-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT07750639)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: Reducing Opioid Use A
 fter Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantit
 y\nEstimated primary completion: 30 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07750639
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06186141-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT06186141)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: Nausea and Vomiting i
 n Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA
 ): Morphine vs Oxycodone\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/oxycodone-xtampza-er#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0618614
 1
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757140-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Oxycodone (Xtampza ER): Phase 1/2 readout est. (NCT06757140)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 1/2.\nStudy: Opioid Drug Interac
 tion Study\nEstimated primary completion: 1 January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06757140
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153003-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Oxycodone (Xtampza ER): Phase 4 readout est. (NCT07153003)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 4.\nStudy: Efficacy And Safety O
 f Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control Aft
 er Primary Total Knee And Total Hip Arthroplasty\nEstimated primary comple
 tion: 1 September 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/oxycodone-xtampza-er#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07153003
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824258-8314@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Oxycodone (Xtampza ER): Phase 1 readout est. (NCT07824258)
DESCRIPTION:Oxycodone (Xtampza ER)\, phase 1.\nStudy: Post-Vasectomy Pain S
 tudy\nEstimated primary completion: 31 December 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07824258
URL:https://assetmemo.bio/drug/oxycodone-xtampza-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
